IOBT iobiotech.com: Enterprise Value to EBITDA Ratio

Graphic logo of IO Biotech (IOBT)

IO Biotech, Inc. (IOBT) develops cancer vaccines while facing pressure from global behemoths in the battle for patents, though asset value growth is being driven by successful melanoma trials and interest from major players. The share price history with the 0.00 metric is available below. The business is currently focusing on the final stages of drug development and selecting partners for global sales.

IO Biotech Corp - IOBT Total Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 04/18/2026)

Summary analytical data breakdowns for iobiotech.com (IOBT)

- stock price and consensus target price:
Stock Quotes IO Biotech Corp|IOBT - Average Forecast Price
- company stock capitalization data:
Market Valuation IO Biotech Inc.|IOBT - Value Adjusted for Debt and Cash
- business book valuation details:
Book Value per Share IO Biotech|IOBT - Book Valuation of Business|Market Value to Book Value Ratio iobiotech.com|IOBT - Cumulative Company Assets
- debt and solvency information:
Debt to Equity IO Biotech, Inc.|IOBT - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio IO Biotech|IOBT - Company Aggregate Debts|Debt to Book Capitalization Ratio IO Biotech Inc.|IOBT - Company Long-Term Indebtedness|Company Short-Term Debt IO Biotech|Quick Liquidity Indicator iobiotech.com
- financial results and valuation multiples details:
IOBT - Annual Net Income|Future Profit IO Biotech, Inc.|IOBT - Market Price to Net Income Ratio|Forward P/E Multiple IO Biotech, Inc.|IOBT - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple IO Biotech Inc.|IOBT - Profit before interest, taxes and amortization|Earnings per share for the last twelve months IO Biotech|IOBT - Earnings per share for the trailing year|Quarterly EPS earnings growth iobiotech.com|IOBT - Earnings growth in current year|Net earnings per share growth forecast for next year IO Biotech, Inc.
Fundamental company analysis:IOBT (IO Biotech Corp)
Original product of IO Biotech Inc

The EV/EBITDA ratio compares the total enterprise value of IO Biotech, Inc. (IOBT) with its operating profit before depreciation and interest. For IO Biotech, Inc. (IOBT), which develops complex cancer vaccines, this metric is critical when evaluating capital-intensive research in immuno-oncology. By analyzing changes in the EV/EBITDA ratio, an investor can determine the real value of the business net of debt. This trend captures the necessary data to avoid overpaying for speculative asset growth.

Competitor analysis for IO Biotech, Inc.

ImmunityBio Corp - Enterprise Value to EBITDA Ratio|Immunocore Corp (IMCR) - Company Value to EBITDA|JANX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RCUS (arcusbio.com)|ZYME: EV/EBITDA Multiple|TNGX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Iovance|Enterprise Value to EBITDA Ratio Immatics Biotechnologies (IMTX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Xencor, Inc. (XNCR)|Enterprise Value to EBITDA Ratio compasstherapeutics.com CMPX|Replimune - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Lyell LYEL|IPHA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PYXS (Pyxis Oncology, Inc.) - Enterprise Value to Operating Income Before Depreciation|cgen.com (CGEN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA sutrobio.com (STRO)|Enterprise Value to EBITDA Ratio INKT|HOWL - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio IMMX (Immix Biopharma, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio ALXO|EV/EBITDA Multiple CUE (Cue Biopharma)|Business Value to Operating Income Before Depreciation PDSB|Sonnet BioTherapeutics Holdings Inc. - EV/EBITDA Multiple|Company Value to EBITDA MAIA Biotech|Liminatus Pharma Corp (LIMN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|LAVA Therapeutics - Business Value to Operating Income Before Depreciation|NXTC (NextCure, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Leap Tx|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Intensity Therapeutics (INTS)|SNSE: Company Value to Operating Income Before Depreciation Ratio|Synthetic Biologics - Enterprise Value to EBITDA Ratio|Gritstone bio Inc. (GRTS) - Company Value to EBITDA|Kineta, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio neximmune.com NEXI|turnstonebio.com (TSBX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Vaccinex Inc. (VCNX)|Enterprise Value to EBITDA Ratio HARP